Nashat Gabrail, MD
Hematology-Oncology · Canton, OHNPI 1104854751
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $444,689 of the $634,530 with a category attached, or 70.1%. 60 manufacturers reported payments, led by Dova Pharmaceuticals at 27.3% of the total. Reporting peaked in 2019 at $152,357 and has fallen 97.1% since, to $4,450 in 2025.
Across 863 payments — averaging $735.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$173K
- Sobi, Inc$110K
- GSK$83K
- Johnson & Johnson$69K
- Karyopharm Therapeutics Inc.$41K
- Pharmacosmos Therapeutics Inc.$40K
- plus $118K from 54 others
Across 2,883 payments — averaging $5824.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3.5M
- Bayer$1.4M
- GSK$1.2M
- Acerta Pharma LLC$950K
- Merck$797K
- Tesaro, Inc.$734K
- plus $8.2M from 54 others
What the payments were for
- Consulting fees$76,78212%
- Speaking & faculty fees$444,68970%
- Travel & lodging$92,43315%
- Food & beverage$20,3973%
- Education$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$280,891
- ZEJULA$111,827
- DARZALEX$67,160
- XPOVIO$40,646
- Monoferric$39,408
- COSELA$15,103
- Venclexta$8,500
- Lonsurf$7,090
- Yescarta$6,920
- YONSA$6,573
- Vitrakvi$3,122
- CALQUENCE$2,745
- Leukine$2,100
- SARCLISA$1,856
- ABECMA$1,838
- Luspatercept$1,249
- Oral Paclitaxel$800
- Encequidar$800
- LYNPARZA$525
- IMFINZI$525
How this compares
Too few hematology-oncology providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 23 | $900,712 |
| IbrancePalbociclib | 55 | $859,099 |
| InrebicFedratinib Dihydrochloride | 13 | $344,460 |
| RevlimidLenalidomide | 18 | $314,431 |
| DopteletAvatrombopag Maleate | 24 | $296,616 |
| JakafiRuxolitinib Phosphate | 17 | $287,702 |
| ProcritEpoetin Alfa | 133 | $132,037 |
| ZarxioFilgrastim-Sndz | 121 | $106,202 |
| RuxienceRituximab-Pvvr | 14 | $88,271 |
| Lupron DepotLeuprolide Acetate | 36 | $71,585 |
| XareltoRivaroxaban | 80 | $55,458 |
| EliquisApixaban | 28 | $17,358 |
| Bortezomib | 60 | $8,686 |
| Imatinib Mesylate | 46 | $6,431 |
| Exemestane | 31 | $2,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Ruxience, Eliquis | $218 | $964,72797 claims |
| Bristol Myers SquibbInrebic, Revlimid | $1,277 | $658,89131 claims |
| Dova PharmaceuticalsDoptelet | $173,118 | $296,61624 claims |
| Incyte CorporationJakafi | $5,739 | $287,70217 claims |
| Johnson & JohnsonProcrit, Xarelto | $68,602 | $187,496213 claims |
| AbbVieLupron Depot | $8,620 | $71,58536 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $81 | $13711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Canton
- Samir AbraksiaCleveland$8K
- Abbas KhalilLima$2K
- Peter XieCleveland$122
- Brad PohlmanCleveland$0
- Wesley BoyetteColumbus$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.